Kristofer J. Thurecht

Repurposing Antibody-Drug Conjugates for Theranostic Targeting of Nectin-4 and TROP2 in Bladder Cancer

Abstract The application of antibody-drug conjugate (ADC) therapies in advanced bladder cancers may be improved through non-invasive molecular imaging and therapy with targeted radiation. Enfortumab and Sacituzumab, the antibody components for the ADCs PADCEV (Nectin-4 targeting)...